BioLargo (NASDAQ:BLGO – Get Free Report) is one of 34 public companies in the “Chemicals & allied products” industry, but how does it contrast to its rivals? We will compare BioLargo to similar businesses based on the strength of its valuation, dividends, risk, profitability, institutional ownership, analyst recommendations and earnings.
Insider & Institutional Ownership
0.0% of BioLargo shares are held by institutional investors. Comparatively, 68.4% of shares of all “Chemicals & allied products” companies are held by institutional investors. 20.3% of BioLargo shares are held by company insiders. Comparatively, 10.1% of shares of all “Chemicals & allied products” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations for BioLargo and its rivals, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
BioLargo | 0 | 0 | 0 | 0 | N/A |
BioLargo Competitors | 139 | 1271 | 1591 | 46 | 2.51 |
Volatility & Risk
BioLargo has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s rivals have a beta of 1.78, indicating that their average share price is 78% more volatile than the S&P 500.
Valuation & Earnings
This table compares BioLargo and its rivals gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
BioLargo | $12.23 million | -$3.50 million | -8.06 |
BioLargo Competitors | $6.67 billion | $206.77 million | 65.21 |
BioLargo’s rivals have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares BioLargo and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
BioLargo | -16.53% | -58.35% | -32.12% |
BioLargo Competitors | -568.74% | 5.73% | -0.15% |
Summary
BioLargo rivals beat BioLargo on 8 of the 10 factors compared.
About BioLargo
BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
Receive News & Ratings for BioLargo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLargo and related companies with MarketBeat.com's FREE daily email newsletter.